Biocon raises R&D expenditure by 15%

26 Jul 2014 Evaluate

Biotech major Biocon has increased its gross Research and Development (R&D) expenditure by nearly 15 per cent. The company, which has R&D as a key focus, saw its gross R&D spends at Rs 54 crore, which is about 10 per cent of the company’s biopharma revenues and was Rs 7 crore over and above its gross R&D spend during the corresponding quarter of the previous year. Of the gross R&D spend of Rs 54 crore, the company’s net R&D spend was Rs 31 crore. Moreover, the company capitalised around Rs 16 crore of the development costs and Rs 7 crore came from the deferred revenues from the annulled deal with Pfizer.

The company has reported 10.06% rise in its consolidated net profit after taxes & Minority interest at Rs 102.91 crore for the quarter as compared to Rs 93.50 crore for the same quarter in the previous year. Total income has increased by 2.59% at Rs 741.95 crore for quarter under review as compared to Rs 723.17crore for the quarter ended June 30, 2013.

Biocon Share Price

371.25 -1.40 (-0.38%)
23-Jan-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.40
Dr. Reddys Lab 1246.40
Cipla 1373.05
Zydus Lifesciences 891.90
Lupin 2151.30
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×